Disruptive Tech Research
  • About
  • Media
  • Research
  • Subscribe
  • Log in
Select Page
[IMNM] Biotech Absurdity

[IMNM] Biotech Absurdity

by Lou Basenese | Apr 27, 2022 | IMNM

Low float stocks are prone to major moves on nominal volume. Unfortunately in both directions. Here’s what’s going on with IMNM…

[IMNM] One Big Step Closer To Escape Velocity

[IMNM] One Big Step Closer To Escape Velocity

by Lou Basenese | Apr 26, 2021 | IMNM

The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)

[IMNM] New Data Puts Us One Step Closer to $100+ Per Share

[IMNM] New Data Puts Us One Step Closer to $100+ Per Share

by Lou Basenese | Feb 18, 2021 | IMNM

The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)

[IMNM] New Data Makes Stock A (Screaming) Buy

[IMNM] New Data Makes Stock A (Screaming) Buy

by Lou Basenese | Feb 1, 2021 | IMNM

The latest data out of Immunome underscores the superiority of its approach and adds urgency to the opportunity. Here’s why…

[IMNM] Biotech Absurdity

[New Pick] Preparing For Second-Order Covid-19 Profits

by Lou Basenese | Jan 11, 2021 | Trade Alerts

With micro-caps surging and the Covid-19 pandemic underscoring the vital need for new drugs and therapies, this micro-cap is perfectly positioned to capitalize on the momentum in both areas of the market.

Your account

Sign in

Research Links

  • Real-Time Blog
  • Active Recs
  • Archive

Recent Posts

  • Q2 2022 Portfolio Review & Outlook
  • ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report
  • [IMNM] Biotech Absurdity
  • [Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
  • [Video] ATOM: 5 Key Takeaways From The Q4 2021 Report
  • RESN: Time To Lock In Our 5G Gains
  • [CUE] “That Data Is Amazing!” So Why Is The Stock Down?